• norsk
    • English
  • norsk 
    • norsk
    • English
  • Logg inn
Vis innførsel 
  •   Hjem
  • Faculty of Medicine
  • Department of Clinical Medicine
  • Department of Clinical Medicine
  • Vis innførsel
  •   Hjem
  • Faculty of Medicine
  • Department of Clinical Medicine
  • Department of Clinical Medicine
  • Vis innførsel
JavaScript is disabled for your browser. Some features of this site may not work without it.

Molecular Subtypes of Breast Cancer: Long-term Incidence Trends and Prognostic Differences

Valla, Marit; Vatten, Lars Johan; Engstrøm, Monica J; Haugen, Olav Anton; Akslen, Lars A.; Bjørngaard, Johan Håkon; Hagen, Anne Irene; Ytterhus, Borgny; Bofin, Anna M.; Opdahl, Signe
Peer reviewed, Journal article
Accepted version
Thumbnail
Åpne
Accepted version (1.863Mb)
Permanent lenke
https://hdl.handle.net/1956/17795
Utgivelsesdato
2016-12
Metadata
Vis full innførsel
Samlinger
  • Department of Clinical Medicine [1573]
Originalversjon
https://doi.org/10.1158/1055-9965.epi-16-0427
Sammendrag
Background: Secular trends in incidence and prognosis of molecular breast cancer subtypes are poorly described. We studied long-term trends in a population of Norwegian women born 1886–1977. Methods: A total of 52,949 women were followed for breast cancer incidence, and 1,423 tumors were reclassified into molecular subtypes using IHC and in situ hybridization. We compared incidence rates among women born 1886–1928 and 1929–1977, estimated age-specific incidence rate ratios (IRR), and performed multiple imputations to account for unknown subtype. Prognosis was compared for women diagnosed before 1995 and in 1995 or later, estimating cumulative risk of death and HRs. Results: Between 50 and 69 years of age, incidence rates of Luminal A and Luminal B (HER2−) were higher among women born in 1929 or later, compared with before 1929 [IRRs 50–54 years; after imputations: 3.5; 95% confidence interval (CI), 1.8–6.9 and 2.5; 95% CI, 1.2–5.2, respectively], with no clear differences for other subtypes. Rates of death were lower in women diagnosed in 1995 or later, compared to before 1995, for Luminal A (HR 0.4; 95% CI, 0.3–0.5), Luminal B (HER2−; HR 0.5; 95% CI, 0.3–0.7), and Basal phenotype (HR 0.4; 95% CI, 0.2–0.9). Conclusions: We found a strong secular incidence increase restricted to Luminal A and Luminal B (HER2−) subtypes, combined with a markedly improved prognosis for these subtypes and for the Basal phenotype.
Utgiver
American Association for Cancer Research
Tidsskrift
Cancer Epidemiology, Biomarkers and Prevention
Opphavsrett
Copyright 2016 American Association for Cancer Research

Kontakt oss | Gi tilbakemelding

Personvernerklæring
DSpace software copyright © 2002-2019  DuraSpace

Levert av  Unit
 

 

Bla i

Hele arkivetDelarkiv og samlingerUtgivelsesdatoForfattereTitlerEmneordDokumenttyperTidsskrifterDenne samlingenUtgivelsesdatoForfattereTitlerEmneordDokumenttyperTidsskrifter

Min side

Logg inn

Statistikk

Besøksstatistikk

Kontakt oss | Gi tilbakemelding

Personvernerklæring
DSpace software copyright © 2002-2019  DuraSpace

Levert av  Unit